Your Team for Swiss Law – now also in Geneva

Search filters

BACHEM completes Capital Increase

VISCHER advises on the capital increase of BACHEM HOLDING AG as transaction counsel. As a result of the capital increase, in which 400'000 new shares were issued, BACHEM (SIX: BANB) received gross proceeds of CHF 48 million, which...

Warteck Invest completes Capital Increase

VISCHER advises on the capital increase of Warteck Invest AG as transaction counsel. Warteck Invest is one of the oldest real estate companies listed on the SIX Swiss Exchange and is focusing on residential and business properties...

Kuros Biosciences enters convertible bond agreement

Kuros Biosciences AG (Kuros) entered into a convertible bond financing agreement with Nice & Green SA for up to a maximum of CHF 5 million. The facility is provided by Nice & Green SA (N&G), a private Swiss company which...

Ricoh acquires Lake Solutions AG

The world-wide active Ricoh technology group acquires all shares in Lake Solutions AG, a leading Swiss ICT solutions Provider.

VISCHER advises the selling shareholders. The team is led by Felix W. Egli (Partner, Corporate/M&A)...

wefox Group raises USD 125 million in B round

wefox Group, the Berlin-based insurtech firm with headquarter in Zurich has successfully raised USD 125 million for its series B round. The USD 125 million investment is the largest series B round for an insurtech company...

New shareholder structure for Alpiq

VISCHER AG has advised the minority shareholder EBL (Genossenschaft Elektra Baselland) with regard to the new shareholder structure of Alpiq. The VISCHER team comprised David Jenny (Partner, Corporate/M&A), Stefan Grieder...

Freezing order: leading case Swiss Federal Court

In a leading case on 3 April 2019, the Swiss Federal Supreme Court ruled that improper novas, i.e. facts that arose before the decision of the first instance, are admissible in attachment opposition proceedings before the second...

NUMAB concludes Licensing and Development Agreement in China

Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...

ALENTIS Therapeutics raises CHF 12.5m in Series A Financing

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5 million. ALENTIS’ lead program is a...

Polyneuron raises CHF 22.5 million in a major Series A financing

Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced the closing of an oversubscribed CHF22.5 million Series A financing. The round was...

You are currently offline. Some pages or content may fail to load.